Clinical Effect of Shenkang Injection Combined with Calcium Hydroxybenzenesulfonate Capsule on Immune Function, Cytokine Balanceand Renal Function in Patients withPNS

  • Jianzhong Dang
Keywords: Calcium hydroxybenzenesulfonate; Primary nephrotic syndrome; Immune function; Cytokine balance; Lipid metabolism

Abstract

In this paper, we investigated the effects of Shenkang injection combined with calcium hydroxybenzenesulfonate capsule on immune function, cytokine balance, lipid metabolism and renal function in patients with primary nephrotic syndrome. Methods: Ninety-four patients with primary nephrotic syndrome who were diagnosed and treated in our hospital from May 2017 to May 2018 were divided into control group (calcium hydroxybenzenesulfonate capsule) according to different treatment methods. The study group (Xinkang injection combined with calcium hydroxybenzenesulfonate capsule), 47 patients in each group, statistical analysis of the total effective rate of treatment, renal function, immune function, cytokine balance, lipid metabolism before and after treatment The change. Results: After treatment, the total effective rate of treatment group (74.47%) was significantly higher than that of the control group (46.81%) (χ2=7.1329, P=0.0089). The Alb and Ccr of the study group were significantly higher than the control group (P<0.05). The ET, Scr, 24h UPQ and BUN were significantly lower than the control group (P<0.05). The IgA, IgM and IgG in the study group were significantly higher than the control group (P<0.05). The study group CD4+, CD3+, CD8+, CD4+/CD8+ The levels of TNF-α, IL-6 and CRP in the study group were significantly lower than those in the control group (P<0.05). The cholesterol and triglyceride in the study group were significantly lower than those in the control group (P<0.05). <0.05). Conclusion: Shenkang injection combined with calcium hydroxybenzenesulfonate capsule can significantly improve the immune function, lipid metabolism, renal function, reduce cellular inflammatory factors and improve clinical treatment efficiency in patients with primary nephrotic syndrome.

Published
2020-01-01